Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
06 mai 2019 16h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
15 avr. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
06 févr. 2019 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patients...
FibroGen Reports First Quarter 2018 Financial Results
09 mai 2018 16h02 HE
|
FibroGen, Inc
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00...
Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
26 févr. 2018 07h00 HE
|
Summit Therapeutics plc
MRS-T2 Data Provide Evidence of Early Impact of Ezutromid on Downstream Muscle HealthData Build on Positive Biopsy Findings that Showed Significant Decrease in Muscle Damage OXFORD, United Kingdom,...
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
06 déc. 2017 02h00 HE
|
Summit Therapeutics plc
LIESTAL, Switzerland, OXFORD, England and CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Santhera Pharmaceuticals (SIX:SANN), Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), Catabasis...
Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy
25 sept. 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress
14 juin 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, June 14, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
aTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy
24 avr. 2017 07h30 HE
|
aTyr Pharma Inc.
- 63% of Patients Observed Increased Muscle Strength - - Resolaris Demonstrated a Generally Well-Tolerated Safety Profile in Younger Patient Population - SAN DIEGO, April 24, 2017 (GLOBE NEWSWIRE)...
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
29 mars 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, March 29, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...